Givastomig

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 11:12:46 GMT 2025` Edited by `admin` on `Wed Apr 02 11:12:46 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	8MSM5N7RMK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Givastomig

Official Name

English

Fused G1-scFv lambda-heavy chain humanized (1-716) [gamma1 heavy chain anti-CLDN18 humanized (1-450) [VH (Homo sapiens IGHV1-3*01 (85.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120)-Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1,

Preferred Name

English

givastomig [INN]

Common Name

English

Givastomig [WHO-DD]

Common Name

English

Immunoglobulin G1 [300-alanine], anti-(claudin CLDN18.2) (human-Mus musculus ?1-chain) fusion protein with peptide linker ((GGGGS)3) fusion protein with immunoglobulin anti-(tumor necrosis factor receptor TNFRSF9) (human-Mus musculus single-chain variabl

Common Name

English

Immunoglobulin G1-scFv_L-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J)isoform 2, extracellular domain 1 (EC1)], anti-[Homo sapiens TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA,

Common Name

English

Code System Code Type Description

SMS_ID

300000051897

Created by admin on Wed Apr 02 11:12:46 GMT 2025 , Edited by admin on Wed Apr 02 11:12:46 GMT 2025

PRIMARY

INN

12650

Created by admin on Wed Apr 02 11:12:46 GMT 2025 , Edited by admin on Wed Apr 02 11:12:46 GMT 2025

PRIMARY

FDA UNII

8MSM5N7RMK

Created by admin on Wed Apr 02 11:12:46 GMT 2025 , Edited by admin on Wed Apr 02 11:12:46 GMT 2025

PRIMARY

NCI_THESAURUS

C180884

Created by admin on Wed Apr 02 11:12:46 GMT 2025 , Edited by admin on Wed Apr 02 11:12:46 GMT 2025

PRIMARY

CAS

2762499-30-7

Created by admin on Wed Apr 02 11:12:46 GMT 2025 , Edited by admin on Wed Apr 02 11:12:46 GMT 2025

PRIMARY

From	To
4_140	4_200
4_23	4_94
3_140	3_200
3_23	3_94
2_617	2_691
2_568	2_639
2_487	2_554
2_370	2_428
2_264	2_324
2_223	4_220
2_147	2_203
2_22	2_96
1_617	1_691
1_568	1_639
1_487	1_554
1_370	1_428
1_264	1_324
1_232	2_232
1_229	2_229
1_223	3_220
1_147	1_203
1_22	1_96

Related Record Type Details


					7VWM3OLK0G

TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9

TARGET -> ACTIVATOR

Comments:

Pre-clinical

Amount:


					O86SW5D7BQ

CLAUDIN 18 SPLICE VARIANT 2

TARGET->LIGAND

Comments:

Pre-clinical

Amount:

Related Record Type Details


					8MSM5N7RMK

ACTIVE MOIETY

Comments:

TJ033721 is designed to promote 4-1BB clustering by bridging T cells with CLDN18.2-positive tumor cells

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL